found that LINC00152 inhibits the production of Th1-type chemokines CXCL9 and CXCL10 by binding to the enzymatic subunit EZH2 of PPC2, reducing the number of tumor-infiltrating CD8+ T cells and thereby contributing to tumor progression (82). Here, CXCL10 is linked to neoplasm.